Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo‐controlled, double‐blind study
Identifieur interne : 000113 ( Main/Exploration ); précédent : 000112; suivant : 000114Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo‐controlled, double‐blind study
Auteurs : István Sziklai [Hongrie] ; Judit Szilvássy [Hongrie] ; Zoltán Szilvássy [Hongrie]Source :
- The Laryngoscope [ 0023-852X ] ; 2011-04.
English descriptors
- KwdEn :
Abstract
Objectives/Hypothesis:: Since the concept of tinnitus dopaminergic pathway emerged, studies have been proposed to investigate if dopaminergic agents influence tinnitus. We hypothesized that pramipexole, an agonist on D2/D3 receptors, may antagonize tinnitus in the presbycusis patients (in the frequency range of 250 to 8,000 Hz) in a dose schedule accepted for the treatment of Parkinson's disease in elderly people. Study Design:: We designed a randomized, prospective, placebo‐controlled and double‐blind trial. Methods:: Forty presbycusis patients aged 50 years or older with subjective tinnitus were randomized to two groups (20 patients in both). Patients in the drug group took pramipexole over a period of 4 weeks according to a treatment schedule as follows: week 1, 0.088 mg t.i.d.; week 2, 0.18 mg t.i.d.; week 3, 0.7 mg t.i.d.; week 4, 0.18 mg t.i.d. over 3 days and 0.088 mg t.i.d. the rest of the week. Patients in the second group received placebo. Determination of subjective grading of tinnitus perception, the tinnitus handicap inventory (THI) questionnaire and electrocochleography (ECOG) examinations served as the end points. Subjective audiometry was used to produce secondary data. A significant improvement in tinnitus annoyance is found in the group treated with pramipexole versus placebo with respect to inhibition of tinnitus and a decrease of tinnitus loudness greater than 30 dB. However, neither ECOG nor subjective pure‐tone threshold audiometry revealed any change in hearing threshold in response to either pramipexole or placebo. Conclusions:: Pramipexole is an effective agent against subjective tinnitus associated with presbycusis at a dose schedule used for the treatment of Parkinson's disease. The drug did not change hearing threshold. Laryngoscope, 2011
Url:
DOI: 10.1002/lary.21461
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo‐controlled, double‐blind study</title><author><name sortKey="Sziklai, Istvan" sort="Sziklai, Istvan" uniqKey="Sziklai I" first="István" last="Sziklai">István Sziklai</name></author><author><name sortKey="Szilvassy, Judit" sort="Szilvassy, Judit" uniqKey="Szilvassy J" first="Judit" last="Szilvássy">Judit Szilvássy</name></author><author><name sortKey="Szilvassy, Zoltan" sort="Szilvassy, Zoltan" uniqKey="Szilvassy Z" first="Zoltán" last="Szilvássy">Zoltán Szilvássy</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CE6A97D88B5C1EEEDF8341E597B4CD5BDD4A0CAC</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/lary.21461</idno><idno type="url">https://api.istex.fr/document/CE6A97D88B5C1EEEDF8341E597B4CD5BDD4A0CAC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002F11</idno><idno type="wicri:Area/Main/Curation">002B23</idno><idno type="wicri:Area/Main/Exploration">000113</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo‐controlled, double‐blind study</title><author><name sortKey="Sziklai, Istvan" sort="Sziklai, Istvan" uniqKey="Sziklai I" first="István" last="Sziklai">István Sziklai</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Departments of Oto‐Rhino‐Laryngology and Head and Neck Surgery , University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Szilvassy, Judit" sort="Szilvassy, Judit" uniqKey="Szilvassy J" first="Judit" last="Szilvássy">Judit Szilvássy</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Departments of Oto‐Rhino‐Laryngology and Head and Neck Surgery , University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Szilvassy, Zoltan" sort="Szilvassy, Zoltan" uniqKey="Szilvassy Z" first="Zoltán" last="Szilvássy">Zoltán Szilvássy</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Pharmacology and Pharmacotherapy, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">The Laryngoscope</title><title level="j" type="abbrev">The Laryngoscope</title><idno type="ISSN">0023-852X</idno><idno type="eISSN">1531-4995</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-04">2011-04</date><biblScope unit="volume">121</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="888">888</biblScope><biblScope unit="page" to="893">893</biblScope></imprint><idno type="ISSN">0023-852X</idno></series><idno type="istex">CE6A97D88B5C1EEEDF8341E597B4CD5BDD4A0CAC</idno><idno type="DOI">10.1002/lary.21461</idno><idno type="ArticleID">LARY21461</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0023-852X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Idiopathic tinnitus</term><term>Level of Evidence: 1b.</term><term>electrocochleography (ECOG)</term><term>pramipexole</term><term>tinnitus handicap inventory (THI)</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives/Hypothesis:: Since the concept of tinnitus dopaminergic pathway emerged, studies have been proposed to investigate if dopaminergic agents influence tinnitus. We hypothesized that pramipexole, an agonist on D2/D3 receptors, may antagonize tinnitus in the presbycusis patients (in the frequency range of 250 to 8,000 Hz) in a dose schedule accepted for the treatment of Parkinson's disease in elderly people. Study Design:: We designed a randomized, prospective, placebo‐controlled and double‐blind trial. Methods:: Forty presbycusis patients aged 50 years or older with subjective tinnitus were randomized to two groups (20 patients in both). Patients in the drug group took pramipexole over a period of 4 weeks according to a treatment schedule as follows: week 1, 0.088 mg t.i.d.; week 2, 0.18 mg t.i.d.; week 3, 0.7 mg t.i.d.; week 4, 0.18 mg t.i.d. over 3 days and 0.088 mg t.i.d. the rest of the week. Patients in the second group received placebo. Determination of subjective grading of tinnitus perception, the tinnitus handicap inventory (THI) questionnaire and electrocochleography (ECOG) examinations served as the end points. Subjective audiometry was used to produce secondary data. A significant improvement in tinnitus annoyance is found in the group treated with pramipexole versus placebo with respect to inhibition of tinnitus and a decrease of tinnitus loudness greater than 30 dB. However, neither ECOG nor subjective pure‐tone threshold audiometry revealed any change in hearing threshold in response to either pramipexole or placebo. Conclusions:: Pramipexole is an effective agent against subjective tinnitus associated with presbycusis at a dose schedule used for the treatment of Parkinson's disease. The drug did not change hearing threshold. Laryngoscope, 2011</div></front></TEI><affiliations><list><country><li>Hongrie</li></country></list><tree><country name="Hongrie"><noRegion><name sortKey="Sziklai, Istvan" sort="Sziklai, Istvan" uniqKey="Sziklai I" first="István" last="Sziklai">István Sziklai</name></noRegion><name sortKey="Szilvassy, Judit" sort="Szilvassy, Judit" uniqKey="Szilvassy J" first="Judit" last="Szilvássy">Judit Szilvássy</name><name sortKey="Szilvassy, Zoltan" sort="Szilvassy, Zoltan" uniqKey="Szilvassy Z" first="Zoltán" last="Szilvássy">Zoltán Szilvássy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000113 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000113 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CE6A97D88B5C1EEEDF8341E597B4CD5BDD4A0CAC
|texte= Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo‐controlled, double‐blind study
}}
| This area was generated with Dilib version V0.6.23. |  |